Market Cap 1.60B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 16,938,000
Avg Vol 5,114,992
Day's Range N/A - N/A
Shares Out 305.27M
Stochastic %K 62%
Beta 1.02
Analysts Strong Sell
Price Target $9.14

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
CPAADVANCED
CPAADVANCED May. 13 at 10:08 AM
$ABCL The interesting thing about this company is that they have developed an engine that can produce drug candidates faster and with a higher chance of success. As with any pharma, drug candidates can look promising and still fail at latter phases. If the first few drugs pan out this could be a monster of a stock in the Regeneron type price. There is also the possibility of another "covid" coming along that would this time be developed internally and the entire revenue could flow back to ABCL. The institutions see the possibilities here and are increasingly getting on board. Great stock to buy and tuck away for the next 5 years as this plays out IMO.
0 · Reply
snowPOW
snowPOW May. 13 at 7:27 AM
$ABCL $BB exactly, this is social media and should be treated as such. The analysts that print stories up or down only benefits themselves like a car salesman and should be trusted equally to random posters. Fiduciary duty matters! Understand who has to give it to you and who doesn't. Analysts and social media posters certainly don't have it!
0 · Reply
snowPOW
snowPOW May. 13 at 7:18 AM
$ABCL underlying asset improves and share price goes down... That's not weird to you?
1 · Reply
Warbucks007
Warbucks007 May. 13 at 4:51 AM
$ABCL I gave some crap to the pumpers going not stop about a year ago. Trimmed my position then but still have a decent position. Company is executing. We are still a ways away from running up. Temp check on the board is the shorts seem desperate. Pumpers still at it. We got time. Carl will lead this through. Hold for the prize. Not a bad time to add for the rise that will come in another few years
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 2:15 AM
$ABCL More Upgrades
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 12:43 AM
$ABCL I bought more $ABCL today at the open... and again at the close 😆
0 · Reply
tradersunion353
tradersunion353 May. 13 at 12:41 AM
$ABCL SICK board.. folks here has been constantly celebrating every time stock drops stock has been down for last 5 years... POS is down on Ph1 data... Sick mentality
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 12:04 AM
$ABCL To follow up on this. Looks like shorts covered about 3m shares as of the end of April. Still over 44m shares short on $ABCL . I’ll be curious to see where this trends now that we have positive phase 1 data out. And huge volume today. Nearly 17m shares traded. Institutions are officially joining the party. Will be interesting to see what updated institutional holdings are moving forward.
0 · Reply
TradeWinner
TradeWinner May. 12 at 10:40 PM
$ABCL if anyone thinks the post on here move a stock up or down they are delusional. Almost 17 million shares today is not retail. But bodes well!!!
2 · Reply
HeIsHavingHisBath
HeIsHavingHisBath May. 12 at 9:22 PM
$ABCL Oh, look, the bot pumpers like each other's posts too to make legit investors think there's crowd support to their fluffing.
1 · Reply
Latest News on ABCL
AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 1 day ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 1 day ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 8 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 4 weeks ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575


AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 9 months ago

AbCellera price target raised to $7 from $5 at BMO Capital


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera assumed with an Outperform at Leerink

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink


Unusually active option classes on open June 11th

2025-06-11T13:45:23.000Z - 11 months ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


CPAADVANCED
CPAADVANCED May. 13 at 10:08 AM
$ABCL The interesting thing about this company is that they have developed an engine that can produce drug candidates faster and with a higher chance of success. As with any pharma, drug candidates can look promising and still fail at latter phases. If the first few drugs pan out this could be a monster of a stock in the Regeneron type price. There is also the possibility of another "covid" coming along that would this time be developed internally and the entire revenue could flow back to ABCL. The institutions see the possibilities here and are increasingly getting on board. Great stock to buy and tuck away for the next 5 years as this plays out IMO.
0 · Reply
snowPOW
snowPOW May. 13 at 7:27 AM
$ABCL $BB exactly, this is social media and should be treated as such. The analysts that print stories up or down only benefits themselves like a car salesman and should be trusted equally to random posters. Fiduciary duty matters! Understand who has to give it to you and who doesn't. Analysts and social media posters certainly don't have it!
0 · Reply
snowPOW
snowPOW May. 13 at 7:18 AM
$ABCL underlying asset improves and share price goes down... That's not weird to you?
1 · Reply
Warbucks007
Warbucks007 May. 13 at 4:51 AM
$ABCL I gave some crap to the pumpers going not stop about a year ago. Trimmed my position then but still have a decent position. Company is executing. We are still a ways away from running up. Temp check on the board is the shorts seem desperate. Pumpers still at it. We got time. Carl will lead this through. Hold for the prize. Not a bad time to add for the rise that will come in another few years
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 2:15 AM
$ABCL More Upgrades
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 12:43 AM
$ABCL I bought more $ABCL today at the open... and again at the close 😆
0 · Reply
tradersunion353
tradersunion353 May. 13 at 12:41 AM
$ABCL SICK board.. folks here has been constantly celebrating every time stock drops stock has been down for last 5 years... POS is down on Ph1 data... Sick mentality
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 13 at 12:04 AM
$ABCL To follow up on this. Looks like shorts covered about 3m shares as of the end of April. Still over 44m shares short on $ABCL . I’ll be curious to see where this trends now that we have positive phase 1 data out. And huge volume today. Nearly 17m shares traded. Institutions are officially joining the party. Will be interesting to see what updated institutional holdings are moving forward.
0 · Reply
TradeWinner
TradeWinner May. 12 at 10:40 PM
$ABCL if anyone thinks the post on here move a stock up or down they are delusional. Almost 17 million shares today is not retail. But bodes well!!!
2 · Reply
HeIsHavingHisBath
HeIsHavingHisBath May. 12 at 9:22 PM
$ABCL Oh, look, the bot pumpers like each other's posts too to make legit investors think there's crowd support to their fluffing.
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 9:13 PM
$ABCL My god — I can see the parallel here. Alex Karp focused on building Ontology to enable AI to deliver real value, and Carl Hansen seems to take a similar approach in figuring out how to truly apply AI in biotech.
1 · Reply
HeIsHavingHisBath
HeIsHavingHisBath May. 12 at 9:03 PM
$ABCL Like this clown, lol. A pumper still in its maggot stage.
1 · Reply
HeIsHavingHisBath
HeIsHavingHisBath May. 12 at 9:00 PM
$ABCL So weird now, looking back at the histories of some of these pumpers. If I had the inclination I'd chart them across price action and see the overlay.
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 8:54 PM
$ABCL $ABCL I've had a chance to listen to the call again. There is absolutely nothing on the call that was bearish. I'm floored by the progress we've been making and by the team in general. A couple of points that struck me. - we are still on track to nominate/announce another molecule for IND/CTA studies. This will put us at 4 (when you remove 575) - absolutely no liver tox issues at all. ast, alt and bilirubin all in healthy ranges. So, no Hy's Law worries. - 24 day half life to support once monthly dosing - they have a good read on what dosage will be moving forward - 300mg works well for 2ml auto-injector - the modulation of testosterone, LH, and FSH are on point. The more of the drug, the more it was modulated. It was crystal clear. - no serious AEs
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 8:54 PM
$ABCL Another point that stands out. Carl isn't baited into guessing if we will have superior efficacy over Veozah or Lynkuet. He doesn't care if that happens. I'm sure it would be nice but it's not top of mind. All he cares about is equivalent efficacy. This is a great way to manage expectations. He's basically saying "don't buy the stock if you're seeking superior efficacy." IF we do get superior efficacy, then stock can rerate up. But if he gets Wall Street expecting superior and we only get equivalent, then it's a let down. He's not taking the bait.
1 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 8:53 PM
$ABCL Another big highlight for me - they know how to make an antibody for hard to target GPCRs. Their Target Product Profile is explicit - no liver tox, 30 day dosing, and equivalent efficacy. Though we don't know efficacy yet, we DO know that they ARE able to create an antibody that isn't toxic and that gets half-life as expected and allows for 30 day dosing. They are also able to create an antibody that modulates the exact neurons they wanted to modulate for the amount of time they wanted to modulate them. It's literally working just as designed - it's perfection. IF we don't see efficacy in phase 2, then we know that it isn't because the drug didn't do what it was designed to do (it is working perfectly), it's because we didn't know the science well enough. Period
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 8:52 PM
$ABCL The point that I'm making is this: they know how to design a drug to target GPCRs and make it do what they want it to do. The rest is out of their hands. This bodes well for the rest of the pipeline. I may be naive but this makes me more confident about their ability to look at the science and create an antibody that works as intended. Remember, they aren't looking to do science experiments. The science says that hot flashes should alleviate if you modulate these hormones. They can do that. If it doesn't work, then there's a lack of understanding of the science. Ultimately, this is a very important and valuable skill to have and one that should help them lay many golden eggs. I'm more bullish than ever and more excited about the future. Long and strong!
0 · Reply
Ed_Ng
Ed_Ng May. 12 at 8:10 PM
$ABCL clone ones are trying to cheer people to buy so they can unload their bags 😂
0 · Reply
Stocktradesmoon
Stocktradesmoon May. 12 at 7:49 PM
$ABCL $ABCL Stage 1 math What a clean Phase 2 hit in Q3 is actually worth: Phase 3 Odds of success: 55-65% Risk-adj peak sales( 60% of half TAM): $3B × 60% = $1.8B Peak multiple 4.5x = $8.1B PV @ 12% over ~6yrs ≈ $4.1B ABCL635 alone: ~$4-4.5B EV ( 3X from current price) Other buckets: Cash + gov't funding: ~$0.65B Royalty book (bam residual + others): ~$0.3-0.4B Pipeline (575/688/386 + 20 discovery): ~$0.3-0.5B Platform (Trianni/Celium): ~$0.3-0.5B Non-635 total: ~$1.6-2.1B Stage 1 EV: ~$5.6-6.6B ÷ 305M shares = ~$18-22/share = 3.5-4x from $5.24. The biggest single re-rating on the entire ABCL635 path is right here at the Q3 readout. Phase 3 approval.
0 · Reply
DeMampCamp
DeMampCamp May. 12 at 7:37 PM
$ABCL I'm betting we stay around $5 this week due to Options contracts, max pain seems to be around $5 and we all know those greedy market makers don't want anyone winning! With that said, I couldn't care less about Options so it doesn't phase me one bit
1 · Reply
HeIsHavingHisBath
HeIsHavingHisBath May. 12 at 7:24 PM
$ABCL Oh, look, another dude who set up an account last year and only talks about one stock.
1 · Reply
Rastafari
Rastafari May. 12 at 7:06 PM
$ABCL can we close above $5? I say yes!
1 · Reply